R B Song1, C H Vite, C W Bradley, J R Cross. 1. Department of Clinical Studies, School of Veterinary Medicine , University of Pennsylvania, Philadelphia, PA.
Abstract
BACKGROUND: Intracranial neoplasia of dogs is frequently encountered in veterinary medicine, but large-scale studies on prevalence are lacking. OBJECTIVES: To determine the prevalence of intracranial neoplasia in a large population of dogs examined postmortem and the relationship between breed, age, and weight with the presence of primary intracranial neoplasms. ANIMALS: All dogs that underwent postmortem examination from 1986 through 2010 (n = 9,574), including dogs with a histopathologic diagnosis of primary (n = 227) and secondary (n = 208) intracranial neoplasia. METHODS: Retrospective evaluation of medical records from 1986 through 2010. RESULTS: Overall prevalence of intracranial neoplasia in this study's population of dogs was 4.5%. A statistically significant higher prevalence of primary intracranial neoplasms was found in dogs with increasing age and body weights. Dogs ≥15 kg had an increased risk of meningioma (odds ratio 2.3) when compared to dogs <15 kg. The Boxer, Boston Terrier, Golden Retriever, French Bulldog, and Rat Terrier had a significantly increased risk of primary intracranial neoplasms while the Cocker Spaniel and Doberman Pinscher showed a significantly decreased risk of primary intracranial neoplasms. CONCLUSIONS AND CLINICAL IMPORTANCE: Intracranial neoplasia in dogs might be more common than previous estimates. The study suggests that primary intracranial neoplasia should be a strong differential in older and larger breed dogs presenting with signs of nontraumatic intracranial disease. Specific breeds have been identified with an increased risk, and others with a decreased risk of primary intracranial neoplasms. The results warrant future investigations into the role of age, size, genetics, and breed on the development of intracranial neoplasms.
BACKGROUND:Intracranial neoplasia of dogs is frequently encountered in veterinary medicine, but large-scale studies on prevalence are lacking. OBJECTIVES: To determine the prevalence of intracranial neoplasia in a large population of dogs examined postmortem and the relationship between breed, age, and weight with the presence of primary intracranial neoplasms. ANIMALS: All dogs that underwent postmortem examination from 1986 through 2010 (n = 9,574), including dogs with a histopathologic diagnosis of primary (n = 227) and secondary (n = 208) intracranial neoplasia. METHODS: Retrospective evaluation of medical records from 1986 through 2010. RESULTS: Overall prevalence of intracranial neoplasia in this study's population of dogs was 4.5%. A statistically significant higher prevalence of primary intracranial neoplasms was found in dogs with increasing age and body weights. Dogs ≥15 kg had an increased risk of meningioma (odds ratio 2.3) when compared to dogs <15 kg. The Boxer, Boston Terrier, Golden Retriever, French Bulldog, and Rat Terrier had a significantly increased risk of primary intracranial neoplasms while the Cocker Spaniel and Doberman Pinscher showed a significantly decreased risk of primary intracranial neoplasms. CONCLUSIONS AND CLINICAL IMPORTANCE: Intracranial neoplasia in dogs might be more common than previous estimates. The study suggests that primary intracranial neoplasia should be a strong differential in older and larger breed dogs presenting with signs of nontraumatic intracranial disease. Specific breeds have been identified with an increased risk, and others with a decreased risk of primary intracranial neoplasms. The results warrant future investigations into the role of age, size, genetics, and breed on the development of intracranial neoplasms.
Authors: Jennifer W Koehler; Andrew D Miller; C Ryan Miller; Brian Porter; Kenneth Aldape; Jessica Beck; Daniel Brat; Ingrid Cornax; Kara Corps; Chad Frank; Caterina Giannini; Craig Horbinski; Jason T Huse; M Gerard O'Sullivan; Daniel R Rissi; R Mark Simpson; Kevin Woolard; Joanna H Shih; Christina Mazcko; Mark R Gilbert; Amy K LeBlanc Journal: J Neuropathol Exp Neurol Date: 2018-11-01 Impact factor: 3.685
Authors: Michael R Olin; G Elizabeth Pluhar; Brian M Andersen; Rob Shaver; Nate N Waldron; Christopher L Moertel Journal: Crit Rev Immunol Date: 2014 Impact factor: 2.214
Authors: A L Bredlau; M A McCrackin; Anjan Motamarry; Kris Helke; Chao Chen; Ann-Marie Broome; Dieter Haemmerich Journal: Crit Rev Biomed Eng Date: 2016
Authors: Amy K LeBlanc; Christina Mazcko; Diane E Brown; Jennifer W Koehler; Andrew D Miller; C Ryan Miller; R Timothy Bentley; Rebecca A Packer; Matthew Breen; C Elizabeth Boudreau; Jonathan M Levine; R Mark Simpson; Charles Halsey; William Kisseberth; John H Rossmeisl; Peter J Dickinson; Timothy M Fan; Kara Corps; Kenneth Aldape; Vinay Puduvalli; G Elizabeth Pluhar; Mark R Gilbert Journal: Neuro Oncol Date: 2016-05-14 Impact factor: 12.300
Authors: A Courtenay Freeman; Simon R Platt; Shannon Holmes; M Kent; Kelsey Robinson; Elizabeth Howerth; Joe Eagleson; Alexandros Bouras; Milota Kaluzova; Constantinos G Hadjipanayis Journal: J Neurooncol Date: 2018-01-19 Impact factor: 4.130
Authors: Anna Filley; Mario Henriquez; Tanmoy Bhowmik; Brij Nath Tewari; Xi Rao; Jun Wan; Margaret A Miller; Yunlong Liu; R Timothy Bentley; Mahua Dey Journal: J Neurooncol Date: 2018-01-12 Impact factor: 4.130